Cargando…

Metastatic NSCLCs With Limited Tissues: How to Effectively Identify Driver Alterations to Guide Targeted Therapy in Chinese Patients

INTRODUCTION: Molecular diagnostics of newly diagnosed patients with metastatic NSCLC (mNSCLC) with limited tissue samples often face several obstacles in routine practice using next-generation sequencing (NGS), mainly owing to insufficient tissue or DNA; thus, how to effectively identify the molecu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Weihua, Li, Yan, Guo, Lei, Liu, Yutao, Yang, Lin, Ying, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474491/ https://www.ncbi.nlm.nih.gov/pubmed/34590019 http://dx.doi.org/10.1016/j.jtocrr.2021.100167

Ejemplares similares

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study
por: Gu, Linping, et al.
Publicado: (2022)

Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
por: Baldelli, Elisa, et al.
Publicado: (2022)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
por: Lypova, Nadiia, et al.
Publicado: (2021)

Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation
por: Suda, Kenichi
Publicado: (2020)

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
por: Wang, Mingxing, et al.
Publicado: (2017)

The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs
por: Bortolotto, Chandra, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
por: Capalbo, Carlo, et al.
Publicado: (2019)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Cucurbitacin D Overcomes Gefitinib Resistance by Blocking EGF Binding to EGFR and Inducing Cell Death in NSCLCs
por: Hong, Se Hyang, et al.
Publicado: (2020)

Anti-angiogenic efficacy of 5′-triphosphate siRNA combining VEGF silencing and RIG-I activation in NSCLCs
por: Yuan, Dongmei, et al.
Publicado: (2015)

Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs
por: Chen, Feihong, et al.
Publicado: (2017)

Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
por: Cui, Bopei, et al.
Publicado: (2023)

Annexin A2 Silencing Inhibits Proliferation and Epithelial-to-mesenchymal Transition through p53-Dependent Pathway in NSCLCs
por: Wu, Minhua, et al.
Publicado: (2019)

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock, Alexa B, et al.
Publicado: (2020)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs
por: Du, Liqin, et al.
Publicado: (2010)

Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis
por: Lan, Bo, et al.
Publicado: (2022)

Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma
por: Shih, David J. H., et al.
Publicado: (2020)

How to Design the eHMI of AVs for Urgent Warning to Other Drivers with Limited Visibility?
por: Lim, Dokshin, et al.
Publicado: (2023)

Network-Based Analysis to Identify Drivers of Metastatic Prostate Cancer Using GoNetic
por: de Schaetzen van Brienen, Louise, et al.
Publicado: (2021)

Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study
por: Yang, Jinhua, et al.
Publicado: (2020)

Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations
por: Youn, Ahrim, et al.
Publicado: (2013)

Genomics alterations of metastatic and primary tissues across 15 cancer types
por: Liu, Gang, et al.
Publicado: (2017)

Virtual Screening and Quantitative Structure–Activity Relationship of Moringa oleifera with Melanoma Antigen A (MAGE-A) Genes against the Therapeutics of Non-Small Cell Lung Cancers (NSCLCs)
por: Bhat, Smitha S., et al.
Publicado: (2022)

MEDB-64. Are Rab GTPases metastatic drivers in metastatic medulloblastoma?
por: Entwistle, Susannah, et al.
Publicado: (2022)

Trans‐3,5,4´‐trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl‐2 pathway by upregulation of miR‐345 and miR‐498
por: Lu, Min, et al.
Publicado: (2019)

Clonal Architectures and Driver Mutations in Metastatic Melanomas
por: Ding, Li, et al.
Publicado: (2014)

Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets
por: Lu, Songjian, et al.
Publicado: (2015)

APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors
por: Roper, Nitin, et al.
Publicado: (2019)

Driver gene alterations profiling of Chinese non‐small cell lung cancer and the effects of co‐occurring alterations on immunotherapy
por: Sun, Shengjie, et al.
Publicado: (2021)

Pan-cancer driver copy number alterations identified by joint expression/CNA data analysis
por: Wang, Gaojianyong, et al.
Publicado: (2020)

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer
por: Pereira, Bernard, et al.
Publicado: (2021)

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
por: Medford, Arielle J., et al.
Publicado: (2019)

Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report
por: Song, Peng, et al.
Publicado: (2019)

EGFR mutation is positively correlated with C-Met protein expression: a study of 446 resected lung adenocarcinoma
por: Lei, Huizi, et al.
Publicado: (2021)

Limitations and usefulness of biopsy techniques for the diagnosis of metastatic bone and soft tissue tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
por: Schwartzberg, Lee S., et al.
Publicado: (2022)

Identifying modules of cooperating cancer drivers
por: Klein, Michael I, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ffu0d48o22jseo3uuer7rh38u5